LIDOCAINE INJECTION BP 1 %
LIDOCAINE HYDROCHLORIDE : 1 % · DIN 02462443 · AURO PHARMA INC
Health Canada status: MARKETED
What is LIDOCAINE INJECTION BP?
LIDOCAINE INJECTION BP 1 % contains LIDOCAINE HYDROCHLORIDE : 1 %. It is listed in the Health Canada Drug Product Database under DIN 02462443, held by AURO PHARMA INC, supplied as SOLUTION for BLOCK/INFILTRATION administration. Health Canada currently lists it as marketed, status dated 09-Jun-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LIDOCAINE INJECTION BP used for?
LIDOCAINE INJECTION BP (lidocaine hydrochloride) are indicated for production of local or regional anesthesia by: infiltration techniques including percutaneous injection, peripheral nerve block techniques such as brachial plexus and intercostal blocks, and when the accepted procedures for these techniques, as described in standard textbooks, are observed.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02462443 |
|---|---|
| Brand name | LIDOCAINE INJECTION BP |
| Generic / active ingredient | LIDOCAINE HYDROCHLORIDE : 1 % |
| Manufacturer | AURO PHARMA INC |
| Strength | 1 % |
| Dosage form | SOLUTION |
| Route of administration | BLOCK/INFILTRATION |
| Schedule | Ethical |
| ATC code | N01BB02 LIDOCAINE |
| AHFS class | 72:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Jun-2021 |
| Original market date | 2021-06-09 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
Is LIDOCAINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by HIKMA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N01BB02 LIDOCAINE. 26 of 72 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CATHEJELL | 20 MG | GEL | PHARMAZEUTISCHE FABRIK MONTAVIT GES M.B.H. | MARKETED | DIN 02370840 |
| JELIDO | Strength | Gel | PENDOPHARM DIVISION OF PHARMASCIENCE INC 100 6111 Royalmount Ave Montreal Quebec Canada H4P 2T4 | MARKETED | DIN 02469146 |
| LIDOCAINE HYDROCHLORIDE INJECTION | 10 MG | SOLUTION | LABORATOIRE AGUETTANT | MARKETED | DIN 02500647 |
| LIDOCAINE HYDROCHLORIDE INJECTION | 20 MG | SOLUTION | LABORATOIRE AGUETTANT | MARKETED | DIN 02500655 |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 10 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02421984 |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 10 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 00884154 |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 10 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02422018 |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 10 MG | SOLUTION | FORMATIVE PHARMA INC. | MARKETED | DIN 02534827 |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 20 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 01901982 |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 20 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02421992 |
Who else supplies LIDOCAINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LIDOCAINE appears in 8211 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.